99 related articles for article (PubMed ID: 21961097)
1. Plasma or serum TIMP-1 is a predictor of survival outcomes in colorectal cancer: a meta-analysis.
Lee JH; Choi JW; Kim YS
J Gastrointestin Liver Dis; 2011 Sep; 20(3):287-91. PubMed ID: 21961097
[TBL] [Abstract][Full Text] [Related]
2. Serum TIMP-1 predicts survival outcomes of invasive breast carcinoma patients: a meta-analysis.
Lee JH; Choi JW; Kim YS
Arch Med Res; 2011 Aug; 42(6):463-8. PubMed ID: 21945575
[TBL] [Abstract][Full Text] [Related]
3. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
Holten-Andersen MN; Stephens RW; Nielsen HJ; Murphy G; Christensen IJ; Stetler-Stevenson W; Brünner N
Clin Cancer Res; 2000 Nov; 6(11):4292-9. PubMed ID: 11106246
[TBL] [Abstract][Full Text] [Related]
4. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
[TBL] [Abstract][Full Text] [Related]
5. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
6. A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1.
Nielsen HJ; Christensen IJ; Brünner N
Scand J Gastroenterol; 2010; 45(2):200-7. PubMed ID: 20095885
[TBL] [Abstract][Full Text] [Related]
7. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.
Holten-Andersen MN; Nielsen HJ; Sørensen S; Jensen V; Brünner N; Christensen IJ
Eur J Cancer; 2006 Aug; 42(12):1889-96. PubMed ID: 16809030
[TBL] [Abstract][Full Text] [Related]
8. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Lipton A; Leitzel K; Chaudri-Ross HA; Evans DB; Ali SM; Demers L; Hamer P; Brown-Shimer S; Pierce K; Gaur V; Carney W
J Clin Oncol; 2008 Jun; 26(16):2653-8. PubMed ID: 18443351
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Imada T; Noguchi Y
Anticancer Res; 2004; 24(3b):2101-5. PubMed ID: 15274408
[TBL] [Abstract][Full Text] [Related]
10. Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study.
Birgisson H; Nielsen HJ; Christensen IJ; Glimelius B; Brünner N
Eur J Cancer; 2010 Dec; 46(18):3323-31. PubMed ID: 20619633
[TBL] [Abstract][Full Text] [Related]
11. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Rino Y; Masuda M; Imada T
Oncology; 2007; 72(3-4):205-8. PubMed ID: 18160809
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564
[TBL] [Abstract][Full Text] [Related]
13. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
14. Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer.
Böckelman C; Beilmann-Lehtonen I; Kaprio T; Koskensalo S; Tervahartiala T; Mustonen H; Stenman UH; Sorsa T; Haglund C
BMC Cancer; 2018 Jun; 18(1):679. PubMed ID: 29929486
[TBL] [Abstract][Full Text] [Related]
15. Changes in plasma TIMP-1 levels after resection for primary colorectal cancer.
Frederiksen C; Lomholt AF; Davis GJ; Dowell BL; Blankenstein MA; Christensen IJ; Brünner N; Nielsen HJ
Anticancer Res; 2009 Jan; 29(1):75-81. PubMed ID: 19331135
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
17. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
[TBL] [Abstract][Full Text] [Related]
18. Saliva and plasma TIMP-1 in patients with colorectal cancer: a prospective study.
Holten-Andersen L; Christensen IJ; Jensen SB; Reibel J; Laurberg S; Nauntofte B; Brünner N; Nielsen HJ
Scand J Gastroenterol; 2012 Oct; 47(10):1234-41. PubMed ID: 22871105
[TBL] [Abstract][Full Text] [Related]
19. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
20. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Noguchi Y; Takanashi Y
Br J Surg; 2001 Dec; 88(12):1596-601. PubMed ID: 11736971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]